FIBRX Derm is committed to the development of decorin, an anti-scarring therapy, for Dystrophic Epidermolysis Bullosa, a devastating, genetic, skin blistering disease. Decorin, a naturally occurring protein, binds collagen and facilitates the proper development, maintenance, and repair of structural components of the extracellular matrix. We are developing a gel formulation of human recombinant Decorin, an engineered form of the natural anti-scarring protein, to promote healthy tissue regeneration and reduce excessive scarring. 


FIBRX Derm has obtained venture philanthropy funding from the EB Research Partnership and the EB Medical Research Foundation.

Developing an anti-scarring therapeutic for patients with Dystrophic Epidermolysis Bullosa


FIBRX Derm, Inc.

904 Alvarado Road 

Berkeley, CA 94705